2021 Interim Results Presentation

2616.HK

Sep 2021

1 Presentation Disclaimer

By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following:

The information in this presentation has been prepared by representatives of CStone Pharmaceuticals (the "Company" and, together with its subsidiaries, the "Group") for use in presentations by the Group for information purpose. No part of this presentation will form the basis of, or be relied on in connection with, any contract or commitment or investment decision.

Certain statements contained in this presentation and in the accompanying oral presentation, may constitute forward-looking statements. Examples of such forward-looking statements include those regarding investigational drug candidates and clinical trials and the status and related results thereto, as well as those regarding continuing and further development and commercialization efforts and transactions with third parties. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company’s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the global and regional regulatory environment in the jurisdictions in which the Company’s does business, market volatility, fluctuations in costs and changes to the competitive environment. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational drug candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from the Company’s current analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of the Company’s drug candidates, final and quality controlled verification of data and the related analyses, the expense and uncertainty of obtaining regulatory approval, the possibility of having to conduct additional clinical trials and the Company’s reliance on third parties to conduct drug development, manufacturing and other services. Further, even if regulatory approval is obtained, pharmaceutical products are generally subject to stringent on-going governmental regulation, challenges in gaining market acceptance and competition. These statements are also subject to a number of material risks and uncertainties that are described in the Company’s prospectus published onto the websites of the Company and The Stock Exchange of Hong Kong Limited and the announcements and other disclosures we make from time to time. The reader should not place undue reliance on any forward-looking statements included in this presentation or in the accompanying oral presentation. These statements speak only as of the date made, and the Company is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation.

Forward-looking statements are sometimes identified by the use of forward-looking terminology such as "believe," "expects," "may," "will," "could," "should," "shall," "risk," "intends," "estimates," "plans," "predicts," "continues," "assumes," "positioned" or "anticipates" or the negative thereof, other variations thereon or comparable terminology or by discussions of strategy, plans, objectives, goals, future events or intentions.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. The information set out herein may be subject to updating, revision, verification and amendment and such information may change materially.

This presentation and the information contained herein is highly confidential and being furnished to you solely for your information and may not be reproduced or redistributed in any manner to any other person, in whole or in part. In particular, neither the information contained in this presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in any jurisdiction which prohibits the same except in compliance with applicable securities laws. This presentation and the accompanying oral presentation contains data and information obtained from third-party studies and internal company analysis of such data and information. We have not independently verified the data and information obtained from these sources.

By attending this presentation, you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Group and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Group.

2 Introduction & Overview

3 Introduction & Overview

2021YTD Business Highlights

Successfully launched two FIC products, achieving significant sales in a short period of time. AYVAKIT® (avapritinib) launched in mainland China and Taiwan, China in Commercial May and June, respectively. GAVRETO® (pralsetinib) launched in mainland China in June. Together, they generated revenue* of RMB79 million by 30 June

Primary endpoint met for sugemalimab in stage III NSCLC in “all-comers” setting. Clinical Secured industry-leading 3 NDA approvals to facilitate the above launches, and Development submitted 4 NDAs covering a third FIC product – ivosidenib – and indication / geographic expansion for pralsetinib, avapritinib and sugemalimab

Selected Pfizer’s lorlatinib for co-development in China, deepening the partnership Business established in 2020, and accelerated registration of sugemalimab in multiple Development countries ex China with EQRx

IND accepted for CS2006 (PD-L1×4-1BB×HSA tri-specific) in China, and Pipeline 2.0 completing IND-enabling studies of CS5001 (ROR1 ADC) for global submission

Capital Markets Included in Hang Seng Composite Index and Hong Kong Stock Connect

4 Note: * To-market sales. NDA = New Drug Application, IND = Investigational New Drug, NSCLC = Non-small Cell Lung Cancer, AML= Acute Myeloid Leukemia Introduction & Overview

2616.HK

Full-fledged Biopharma 5 Years Since Company Inception

Industry leading management Solid financial position and team with proven track record ability to support growth and complementary expertise initiatives

Well-balanced oncology portfolio with 15 immuno- Full-fledged biopharma with a premier clinical oncology and precision medicine assets, 7 of development engine, established commercial capabilities which are at commercial/late stage and developing manufacturing capability

Today, CStone has achieved commercialization of multiple products and expanded the global dimensions of its business, establishing its position among the leading biopharmas in China

5 Introduction & Overview

Industry leading management team Leadership with proven track record and complementary expertise

Frank Jiang, MD, PhD Chairman, Chief Executive Officer

Shirley Zhao, MD, MBA Jason Yang, MD, PhD Greater China GM Chief Medical Officer

Archie Tse, MD, PhD Jingrong Li, PhD Chief Scientific Officer Chief Technology Officer

Sanhu Wang, MPH Michael Choi, MBA SVP, GA & RA Chief Business Officer

Note: GA=Government Affairs; RA=Regulatory Affairs 6 Introduction & Overview

Well-balanced oncology portfolio of 15 innovative assets Focused on immuno-oncology and precision medicine

Approval Drug candidate Rights Indication Pre-clinical FIH POC Pivotal NDA Marketed Partner CN5 TW HK US 2L NSCLC Pralsetinib 1L NSCLC (RET) 1L MTC / TC Multiple tumors PDGFRA exon 18 Avapritinib GIST (KIT/PDGFRA) AdvSM1 1L Stage IV NSCLC Stage III NSCLC Sugemalimab Out- 1L GC Mainland China (PD-L1) licensed 1L ESCC R/R ENKTL R/R ENKTL Ex-Greater China R/R AML Ivosidenib (IDH1) 1L AML CS1003 (PD-1) 1L HCC Ex-Greater China Lorlatinib NSCLC 4 (ROS1/ALK) (ALK)

Fisogatinib (FGFR4) HCC

CS1002 (CTLA-4) Solid tumors CS20062 Solid tumors (PD-L1/4-1BB/HSA) CS3002 (CDK4/6) Solid tumors CS3005 (A2aR) Solid tumors Solid tumors CS50013 (ROR1) hematologic malignancies CS2007 (Undisclosed Solid tumors Multi-specific) CS2008 (Undisclosed Solid tumors Multi-specific) CS5002 (Undisclosed Solid tumors ADC) Expedited Note: Assets status denote progress in the region noted in the column titled “Rights”; CN = Mainland China, FIH = First in Human POC = Proof of Concept, NSCLC = Non-small Cell Greater China Global Lung Cancer, MTC = Medullary Thyroid Cancer, TC = Thyroid Cancer, GIST = Gastrointestinal Stromal Tumor, AdvSM = Advanced Systemic Mastocytosis, GC = Gastric Cancer, ESCC registration = Esophageal Squamous Cell Carcinoma, R/R = Relapsed or Refractory, NKTL = Natural KILLER/T Cell Lymphoma, AML= Acute Myeloid Leukemia, HCC = Hepatocellular Carcinoma Greater China Global 1.POC was conducted in the U.S. and no clinical trials have been conducted in China; 2.CS2006 is currently under PhI dose escalation study in Taiwan & IND preparation in mainland 7 China; 3.CStone obtains the exclusive global right to lead development and commercialization of LCB71/CS5001 outside the Republic of Korea; 4. Co-development in Greater China; 5. Mainland China Korea Singapore Interim Business Review

8 Commercial 2 3 4 5 Interim Business Review Established strong commercial foundation with seasoned industry leaders Supporting CStone's oncology leadership with successful launches

• 25+ years of experience in the industry (former Greater China GM of BMS, Allergan, Genzyme) • Built several organizations into industry leaders • Deep experience spanning 30+ product launches and building leading brands in oncology, rare disease & medical aesthetics Shirley Zhao, MD, MBA Greater China GM

Critical mass of CStone Commercial platform: > 300 FTEs by 2021

• Outstanding leadership team with diverse range of experience at MNCs and innovative biotechs • Strong track record with 30+ successful launches in oncology & hematology • Covering approximately 70-80% of potential Sophia Lee Zezhou Wang Philip Chen markets for precision medicines TW & HK Sales Broad Market Access

Note: MNC = multinational company; FTE = Full Time Equivalent

9 Commercial 2 3 4 5 Interim Business Review Launches set industry benchmark for speed of delivery Go-to market strategy enabled rapid and broad day one sales

MNC CStone Quality Speed

GAVRETO® AYVAKIT®

Achieved rapid NMPA approval, Time to reach distribution partners within a shorter timeframe than 6.5 months 4 days from time of arrival in China typically required

Accessible in 64 cities within 30 Accessible in 52 cities within 30 64 cities provinces through DTPs on first day 52 cities provinces through DTPs on first day

Achieved product revenue* of RMB33.6 mn Achieved product revenue* of RMB45.8 mn since launch in Mainland China in May 2021 since launch in Mainland China in June 2021 and in Taiwan, China in June 2021

Note: * To-market sales. MNC = multinational company; Rx = prescription; NMPA = National Medical Products Administration; DTP = Direct-to-Patient 10 (pharmacy); TFDA = Taiwan Food and Drug Administration Commercial 2 3 4 5 Interim Business Review Expanding accessibility of assets on the market Commercial team taking additional steps to bolster sales growth

Reimbursement Coverage Scientific Influence

▪ 20 of the major government and commercial ▪ >7 national treatment & diagnosis guidelines insurance plans have included avapritinib and Now include AYVAKIT®, GAVRETO®, TIBSOVO® pralsetinib in their plans since launch and/ or testing ▪ ~40 million urban population covered with strong reimbursement momentum

11 Commercial 2 3 4 5 Interim Business Review Bolstering commercial potential of pipeline developments Preparing market for indication expansions and upcoming launches

Indication expansion of launched assets Launch preparation of more assets

GAVRETO® SUGEMALIMAB • NSCLC – 1L RET • NSCLC – Stage III fusion + (concurrent & NDA filing to NMPA expected in sequential) Mainland China the second half of 2021 NDA filed to NMPA in Aug 2021 Joint efforts with Pfizer in • MTC – RET-mutant Ex-Greater China NDA filing accepted by NMPA in in Mainland China • NSCLC – 1L Stage Apr 2021 IV (sq & nsq) Joint efforts with EQRx NDA filing accepted by NMPA in • TC – RET fusion + Nov 2020 NDA filing accepted by NMPA in Apr 2021 AYVAKIT® TIBSOVO®

• GIST – PDGFRA • r/r AML – IDH1+ in Mainland China D842V mutant NDA filing accepted by NMPA in in Hong Kong, China Aug 2021 NDA filing accepted by HK DoH in May 2021

12 Note: NMPA = National Medical Products Administration, HK DoH = Hong Kong Department of Health Commercial 2 3 4 5 Interim Business Review Preparing Sugemalimab for full-scale commercial launch Harnessing Pfizer’s commercial leadership/infrastructure in China

US$200mn equity investment with three paths for collaboration

Commercialization of Co-development of 1 Sugemalimab 2 Pfizer assets 3 ▪ Up to $280mm in milestone payments ▪ Two post-PoC oncology assets ▪ Jointly in-license for Greater China ▪ Tiered, mid-to-high teens royalties ▪ CStone to receive double-digit royalties ▪ CStone retains option for co-promotion

Positioning & Pricing & Go-To-Market Key Adoption Market Access Model Differentiation

Next generation Competitive local Broadly cover The ONLY PD-(L)1 PD-(L)1 with global pricing; targeting >4,600 hospitals with superior efficacy branding and new 2022 NRDL inclusion (~90% of market) & safety profile for standard of care to maximize patient both stage III&IV for 1L I/O suitable accessibility NSCLC patients patients

Collaboration achieved Work in progress 13 1 Clinical 3 4 5 Interim Business Review Unrivalled clinical development engine Robust strategy, innovative trial designs and agile execution

Jason Yang, MD, PhD, Chief Medical Officer

➢ A physician scientist and senior executive with 25+ years biomedical research and biopharma R&D experience in oncology ➢ Led 60+ global and China trials, brought over 5 assets (tislelizumab, zanubrutinib, pamiparib, avapritinib and pralsetinib) to market, including zanubrutinib to global market, and 2 additional market approvals pending (sugemalimab and ivosidenib) ➢ Built Beigene’s and CStone’s Clinical Development team & established efficient project centric work models ➢ Ph.D trained with Nobel laureates Dr. Mike Brown and Joseph Goldstein at UT Southwestern Med. Ctr.; Postdoctoral training with Dr. Stuart Schreiber at Harvard University

Innovative Clinical Development Strategy to Set New Track Record in China

Indication strategy: focus on China’s largest Covering 50%+ of total cancer incidences: lung cancer, indications with unmet need gastric cancer, liver cancer and esophagus cancer

Adaptive ph I/II design: seamless transition from Three years from ph I first patient dosed to first NDA filing for dose escalation to multiple POC studies sugemalimab

2 pathologies in one trial: squamous + non-squamous Innovative ph III trial design to accelerate NDA 2 treatment modality population in one trial: concurrent + submission in large indications sequential

Cost effective bridging strategy for accelerated Avapritinib and pralsetinib approved in China two years after approval of in-licensed assets in Greater China IND approval

14 1 Clinical 3 4 5 Interim Business Review Poised for rapid growth with numerous clinical successes Industry leading number of NDA submissions, approvals, data readouts

Roadmap for new product

Indication & geographic expansion of launched products Ivosidenib AML (R/R) Pralsetinib Avapritinib ▪ NDA accepted in Mainland China for R/R AML with priority review NSCLC (1L/2L) GIST ▪ Positive data in Chinese R/R ▪ Positive data from registrational study ▪ NDA accepted in Hong Kong for AML patients accepted for oral in 1L RET fusion-positive NSCLC, with PDGFRA D842V mutant GIST presentation in ESMO 2021 1L/2L NSCLC data accepted for ▪ Oral presentation for GIST in ESMO presentation in WCLC 2021 GI 2021 AML (1L) MTC (RET-mutant) AdvSM ▪ Servier announced positive Positive data from registrational study ▪ ▪ In discussion with CDE regarding topline data from the global in RET-mutant MTC accelerated registration pathway phase 3 study in combination ▪ NDA accepted in Mainland China for for AdvSM with Azacitidine in patients with RET-mutant MTC with BTD and previously untreated IDH1- ▪ Approved in U.S. priority review mutated AML ISM TC (RET fusion-positive) ▪ BTD granted by U.S. FDA for Cholangiocarcinoma ▪ NDA accepted in Mainland China for moderate to severe ISM ▪ Approved in U.S. RET fusion-positive TC with priority review ▪ Registrational trial data expected in ▪ Exploring China bridging 2022 strategy Basket trial Others ▪ Ongoing trial with registration potential ▪ Exploring additional indications, i.e. AML, by partner

Note: BTD = breakthrough designation, NSCLC = Non-small Cell Lung Cancer, MTC = Medullary Thyroid Cancer, TC = Thyroid Cancer, GIST = Gastrointestinal Stromal Tumor, CDE = Center for Drug Evaluation, AdvSM = Advanced Systemic Mastocytosis, ISM = Indolent Systemic Mastocytosis, r/r = relapsed or refractory, AML = Acute Myeloid 15 Leukemia, WCLC = World Conference on Lung Cancer, ESMO = European Society for Medical Oncology 1 Clinical 3 4 5 Interim Business Review Expanding addressable patient population for key assets Trials for additional indications to unlock full commercial potential

~90,000 Pralsetinib 1L NSCLC Avapritinib 2L NSCLC Ivosidenib x225% MTC

PTC

Basket trial

GIST (mPDGFRα）

AdvSM

~40,000 ISM x400% 1L NSCLC Others1 2L NSCLC MTC r/r AML PTC Basket trial 1L AML (IC ineligible) GIST (mPDGFRα） CCA ~10,000 AdvSM r/r AML MDS 2L NSCLC 1L AML (IC ineligible) 2 GIST (mPDGFRα） CCA Others 2021 2022 – 2023 2023 and beyond

Source: Clarivate DRG; Globocan 2020; CStone analysis; NEJM 1. Esophageal cancer, Hepatocellular carcinoma, NSCLC, Cervical cancer, etc.; 2. Colorectal cancer, Prostate cancer, Glioblastoma, Melanoma, etc. NSCLC = Non-small Cell Lung Cancer, MTC = Medullary Thyroid Cancer, PTC = Papillary Thyroid Cancer, GIST = Gastrointestinal Stromal Tumor, AdvSM = Advanced Systemic Mastocytosis, ISM = Indolent Systemic Mastocytosis, R/R = Relapsed or Refractory, AML= Acute Myeloid Leukemia, CCA = 16 cholangiocarcinoma; MDS = Myelodysplastic Syndromes 1 Clinical 3 4 5 Interim Business Review Sugemalimab poised to reshape lung cancer landscape Only PD-(L)1 with efficacy in stage III & IV NSCLC in “all-comers” setting

The first PD-(L)1 to cover the entire advanced Positioned to become physicians’ preferred NSCLC through innovative trial design PD-(L)1 for its broad applicability and safety

■ Differentiated design: Fully-human, full length IgG4 derived from GEMSTONE-301 study Ligand’s OmniRat® platform – minimalizing ADA occurrence; • First ph III trial to cover patients with either retaining ADCP activity for potentially enhanced efficacy concurrent or sequential chemoradiotherapy in ■ Outstanding efficacy: one trial, reflecting real-world clinical practice and covering a broader population • The first PD-L1 in combo with chemo to demonstrate clinical efficacy in both sq and nsq stage IV NSCLC patients, with • Detailed data to be presented in 2021 ESMO PFS HR of 0.48, among the best of all competitor PD-(L)1 • The first PD-(L)1 to demonstrate PFS improvement in patients with stage III NSCLC following concurrent or sequential chemoradiotherapy GEMSTONE-302 study • Superior clinical efficacy also observed in ESCC, GC, R/R ENKTL, etc. “Breakthrough Designation” granted by both • First ph III trial in China to cover 1L patients FDA and CDE with both squamous and non-squamous NSCLC in one trial vs two separate trials, with Hazard ■ Commercial opportunity: Ratio further improved in the final analysis* • I/O drug of choice for advanced stage NSCLC - PFS (HR: 0.48; mPFS: 9.0 vs. 4.9 months) • ~850K addressable stage III & IV NSCLC patients in - OS (HR: 0.67; mOS: 22.8 vs. 17.7 months) China/US/EU5/Japan • Detailed data to be presented in 2021 WCLC • Large addressable patients targeted ongoing registration trial in ESCC, GC and R/R ENKTL

Stage III NSCLC: China NDA filed in August 2021 Stage IV NSCLC: China NDA approval expected in Q4 2021 Working closely with EQRx on NDA submission in multiple countries with U.S. BLA filing expected in 2022 17 Note: Data cutoff: Mar 15th, 2021 1 Clinical 3 4 5 Interim Business Review

Accelerated clinical advancement of sugemalimab Entered the 1st tier of NSCLC from the 12th place with “CStone Speed”

From IND to Stage IV NDA approval Cover both Stage III and Stage IV NSCLC

st 1 PD-(L)1 for the treatment of both stage III th and IV NSCLC in 4 PD-(L)1 all-comer setting approved in both sq & non-sq stage Est. 2022 Q4 Iv NSCLC with BIC potential Take the lead in advancing I/O therapy to th Est. 2021 Q4 12 clinical stage III NSCLC patients by ~2 years PD-(L)1 in China Serve Stage IV NSCLC patients with efficacy 2017 Q4 and safety advantages

18 1 2 BD 4 5 Interim Business Review Growing BD team expands global partnership network Deeper capabilities to support pipeline and commercialization efforts

Michael Choi, Chief Business Officer

➢ 23+ years of experience in biopharmaceutical strategy and business development ➢ Executive experience with Pfizer and Sun Pharma Advanced Research Company ➢ 40+ transactions across 6 continents totaling multiple billion dollars in transaction value

Expanded Global Coverage

Seattle Beijing New York New Jersey Shanghai

Expanded BD Priorities

Commercial BD Pipeline Building Strategic Partnerships

Drive near term cash flow Address clinical unmet need / Build up company capabilities / and ROI on Field Force Generate clinical catalysts Evolve into a global player • Commercial partnerships • China: Clinical post-POC assets • Multi-specific, ADC, AI • Accretive near market assets • Global: Paradigm shifting preclinical assets discovery platforms (e.g. FIC/BIC/FW, multi-specific, ADCs, etc.) • Bio-incubator programs

19 1 2 BD 4 5 Interim Business Review Further deepening our strategic partnership with Pfizer Agreement to co-develop Lorlatinib strengthens lung cancer offering

US$200mn equity investment with three paths for collaboration

Lorlatinib (ROS1/ALK)

Sizable patient Significant unmet Post-PoC asset Pioneering population clinical need with high PoS clinical program

Over 670K diagnosed No approved targeted Demonstrated potent World’s 1st pivotal incidence of NSCLC therapies in TKI and selective study of Lorlatinib on in China, 2-3% of refractory setting, and inhibitory activity ROS1 positive which are ROS1+ limited efficacy of against ROS1- patients in TKI existing treatment for positive advanced refractory setting with patients with brain NSCLC IND filing expected metastases in Q4 2021

Note: TKI = Tyrosine Kinase Inhibitor, PoC = Proof-of-Concept, PoS = Probability of Success Collaboration achieved Work in progress 20 Source: Clarivate DRG; Zhang et al. Prevalence of ROS1 fusion in Chinese patients with non small cell lung cancer, Thorac Cancer 2019 10(1): 47–53. 1 2 BD 4 5 Interim Business Review Preparing sugemalimab for global launch Leveraging EQRx’s business model to penetrate PD-L1 market

US$150mn upfront payment, up to US$1.15bn milestone payments and tiered double-digit royalties on net sales

~US$30bn in market value1 (NSCLC, Gastric, Esophageal)

Rest of US UK EU the world2

First BLA filing Regulatory communications underway in 2022

Working closely with EQRx to accelerate the registration of PD-L1 for NSCLC indications, and collaborating for PD-L1 in other indications and PD-1 in HCC

Source: EQRx roadshow presentation, data based on EvaluatePharma July 2021 and Cowen PD(L)1 market model update Dec 2019 Note: 1. Global drug spend reflects 2026 estimated net prescription drug sales 21 1 2 3 Pipeline 2.0 5 Interim Business Review Translating innovation into safe and effective therapies Accelerating the development of assets from lab to post-POC stage

Archie Tse, MD, PhD, Chief Scientific Officer

➢ 20+ years of experience in translational oncology research covering cytotoxics, targeted agents, and immunotherapies ➢ Oncology TA Head at Daiichi-Sankyo, led the Phase 3 study of pexidartinib, the first systemic therapy approved for tenosynovial giant cell tumor ➢ Oversaw early development of 10+ IO assets of different MOAs and modalities at MSD ➢ M.D-Ph.D, University of Southern California; faculty at Memorial Sloan-Kettering Cancer Center

Abundance of sources for In-house infrastructure in place Sustainably deliver cutting-edge drug dev. ideas for implementation innovative drugs

Clinical Observations Trans- Kanglin Protein DMPK & SAB Research lational Institute Chemistry Toxicology Science/ Pipeline 2.0 Biomarker BD partners FIC/BIC/FW Pharma Molecular iSAT cology/ Project Diagnostics QSP Mgmt. CRO Global rights platforms 1~2 INDs per year Clinical Conferences CI Bioinfor- Early Pharmaco matics Dev. JITRI logy

Note: SAB = Science Advisory Board; JITRI = Jiangsu Industrial Technology Research Institute; FIC = First in class; BIC = Best in class; FW = First wave; 22 iSAT = innovation sourcing and alignment team; QSP = Quantitative System Pharmacology 1 2 3 Pipeline 2.0 5 Interim Business Review Harnessing full potential of next-gen candidates Significant progress developing portfolio of FIC/BIC/FW assets

ADC PCC Declaration IND Submission

CS5001 (ROR1 ADC) 1 of top 3 ADCs globally and the first ADC in China Pre-IND

CS5002 (ADC) Potential BIC with global rights Close to PCC

Multispecific

CS2006 (PD-L1 x 4-1BB x HSA) IND filling accepted 2021/7 Potential BIC with rights in Greater China, Korea and Singapore

CS2007 (Multi-Specific) Global FIC with global rights Discovery / Pre-PCC

CS2008 (Multi-Specific) Global FIC with global rights Discovery / Pre-PCC

23 1 2 3 Pipeline 2.0 5 Interim Business Review ROR1 ADC: an asset with transformational potential FIC/BIC asset in new modality with highly differentiated features

Differentiation In Design Clinical & Business Value

Potentially wider ➢ Potential applications for a wide range therapeutic window of tumor types Fully human mAb v.s. • NSCLC, TNBC, ovarian cancer, leukemia, NHL Controllable quality humanized mAb in VLS- and production 101 and NBE-002 • Over 3M annual incidence globally

Site-specific conjugation Proprietary tumor- ➢ Early promising data have led to for a homogeneous selective cleavable extremely high transaction value in drug antibody ratio linker, highly stable in (“DAR”) (DAR=2) serum ROR1 related deals • Merck acquired VelosBio for $2.75 Bn Tumor-activated PBD Core asset: VLS-101 (phase I/II) dimer toxin prodrug • BI acquired NBE for $1.4 Bn Core asset: NBE-002 (phase I)

Leading Position

1 of top 3 ADCs globally and the first ADC in China

IND filling in US IND filling in Potential accelerated Limited pricing & AU expected by China expected registration path pressure maximizes 2021 in 1H 2022 Fast to market and cost- potential commercial efficient development return of the asset

Note: NSCLC = non-small-cell lung cancer, TNBC = triple negative breast cancer, NHL = non-Hodgkin lymphoma, PBD = pyrrolobenzodiazepine; 24 FIC=First in class, BI = Boehringer Ingelheim 1 2 3 4 Finance & Capital Markets Interim Business Review Healthy financial profile supported by solid execution Well capitalized for growth initiatives and commercial stage operations

• RMB2,447.2 million of cash, cash equivalents and time deposits Cash Balance as of June 30, 2021

• Product revenue*: RMB79.4 million

- GAVRETO (pralsetinib): RMB45.8 million (launched in Mainland China in June 2021)

Key Income - AYVAKIT (avapritinib): RMB33.6 million (launched in Mainland Statement China and Taiwan, China in May 2021 and June 2021 respectively) Metrics • R&D expenses (non-IFRS): RMB444.8 million

• Administrative, selling and marketing expenses (non-IFRS): RMB214.3 million

25 Note: * To-market sales 1 2 3 4 Finance & Capital Markets Interim Business Review Expanding capital markets access Inclusion in key index to support share trading and broaden ownership

• Included in Hang Seng Composite • Included in Hong Kong Stock Connect Index on August 20, 2021, and effective on September 6, 2021 from September 6, 2021

Expecting improved liquidity, more efficient price discovery, and greater diversification of our investor base, in particular more onshore institutional investors in mainland China

26 Business Outlook

27 Business Outlook

Vigorous pace of activity for remainder of 2021 Bringing significant clinical and commercial developments to fruition

Pipeline 2.0 Commercial Clinical & Others

Preparation for new NDA approvals Data readout / presentation IND filings & approvals product & indication launch • Sugemalimab stage IV NSCLC • Sugemalimab stage III NSCLC • ROR1 ADC IND / CTA filing in oral presentation in ESMO • TIBSOVO® r/r AML in Mainland in Mainland China U.S. / Australia • Ivosidenib Chinese R/R AML China • Ivosidenib R/R AML in • Lorlatinib IND filing in oral presentation in ESMO • GAVRETO® 1L NSCLC, MTC, Mainland China (by 2021/ Q1 Mainland China TC in Mainland China 2022) • Sugemalimab stage IV NSCLC oral presentation in WCLC • PD-L1/4-1BB/HSA IND ® approval in Mainland China • GAVRETO in other territories • Pralsetinib 1/2L NSCLC oral • AYVAKIT® in other territories NDA fillings presentation in WCLC • Pralsetinib 1L NSCLC in • Joint efforts with Pfizer for • Pralsetinib MTC data Pilot operation of Mainland China presentation launch of sugemalimab in manufacturing facility Mainland China • Pralsetinib 1L/2L NSCLC in • Sugemalimab ENKTL data • Pilot operation of Taiwan, China presentation • Pralsetinib 1L/2L NSCLC in manufacturing facility in Broader patient access Hong Kong SAR, China Suzhou • 10 commercial health insurance plans and 15+ city insurance • Tendering and hospital listing for GAVRETO® and AYVAKIT®

28 Introduction & Overview

Business outlook for 2022 Unlocking the global potential of our business and portfolio

Maximizing commercial potential with market expansion and penetration Commercial Target 5 NDA approvals of products

Expedite full slate of clinical development programs Clinical Development Expect 5+ NDA filings, 3 data readouts and 3+ registrational trial initiations, expanding our presence in other high-prevalence cancers, along with the established lung portfolio

Drive innovative drug discovery and harness full potential of Pipeline 2.0 Pipeline 2.0 Submit IND for 1~2 highly-differentiated molecule(s) with FIC/BIC/FW potential and global rights, and fully develop current suite of molecules, i.e., ROR1 ADC and PD-L1/4-1BB/HSA tri-specific

Business Support global ambitions with multi-dimensional partnerships Pursue flexible deal structures for in-licensing and other partnerships to support pipeline Development development and commercialization efforts in China and abroad

Prepare for pilot manufacturing operations Manufacturing Submission for manufacturing site and material change and completion of technology transfer for multiple products

29 THANK YOU

2616.HK